Curoverse, a Boston, MA-based developer of an open source software platform for genomic and biomedical big data, raised $1.5m in seed funding.
Backers included Hatteras Venture Partners, Point Judith Ventures, Common Angels, MassVentures, and Boston Global Ventures.
The company intends to use the funds to advance development of its platform (Arvados) and to deliver new products based on it.
Led by Adam Berrey, CEO, Curoverse is developing Arvados, a free and open source software platform for genomic and biomedical big data originally developed by a team of scientists and software engineers led by Alexander Wait Zaranek, Ph.D. in the Church lab at Harvard Medical School.
The platform includes a content addressable distributed storage system and a computational management system designed to make complex analyses easily reproducible. The first deployment of Arvados runs a private cloud with 300 TB of storage and 500 cores that is used for genomic analysis at the Harvard Personal Genome Project and for research work at Harvard Medical School.
Curoverse is available today through a private beta program (http://arvados.org) with the company planning to release their first commercial products in 2014.
FinSMEs
19/12/2013